VE
Vetoquinol S.A.
VETO.PA · PAR
75.70 € +0.26% (+0.20 €)
1M +8.95%
Market Cap 880.0M €
P/E Ratio 15.36x
Div. Yield 1.23%
ROE 10.06%
Bulios Fair Price
58.16 €
23.2% downside
Current Price
75.7 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VETO.PA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
7/9Valuation
88 /100
Cheap P/S 1.67x
P/E 15.36x
P/B 1.49x
Growth
41 /100
Stable FCF growth 8.78%
EPS growth 6.76%
Book val. growth 6.86%
Profitability
62 /100
Moderate Op. margin 13.93%
Gross margin 30.50%
FCF margin 9.77%
Quality
53 /100
Average ROA 7.50%
ROIC 8.96%
Asset turnover 0.69x
Debt
100 /100
Low Int. coverage 252.35x
Debt/Equity 0.03x
Net debt/EBITDA -0.59x
Stability
100 /100
Stable EPS volatility 8.33%
Beta 0.87x
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VETO.PA
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Matthieu Frechin
Employees
2,501
Headquarters
Lure
Upcoming events
25 MAR
Earnings
Upcoming earnings report